Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change

Trevi Therapeutics, Inc. (NASDAQ:TRVI) is one of the 12 best multibagger stocks to buy heading into 2026.

On December 4, 2025, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the appointment of David Hastings as Chief Financial Officer, effective January 6, 2026. This marks a key leadership change amid the company’s transition into a more advanced stage of development. As the company moves into Phase 3 development for Haduvio, management sees Hastings’ 25 years of financial leadership experience across public life sciences companies as valuable. Over the years, he has helped companies raise $2 billion in equity and debt financing. Furthermore, his experience in helping companies thrive through commercialization, scaling operations, and strategic transactions aligns with Trevi’s next phase of growth.

This move comes amid strong clinical momentum, as its lead program advances steadily toward pivotal trials. In chronic cough associated with idiopathic pulmonary fibrosis (IPF), Trevi Therapeutics, Inc. (NASDAQ:TRVI) is preparing to request an End-of-Phase 2 meeting with the FDA in Q4 2025, having already completed key Phase 2 work. The company expects to initiate a Phase 3 program in the first half of 2026.

Reinforcing the company’s transition into Phase 3, the ongoing Phase 1 TIDAL study in IPF patients has shown no safety signals, and the completed drug-drug interaction study has confirmed that nalbuphine ER can be safely co-administered with standard antifibrotic therapies. Trevi Therapeutics, Inc. (NASDAQ:TRVI) has also presented topline Phase 2b CORAL data, increasing clinical and investor visibility.

With a cash balance of $194.9 million as of the end of Q3 2025, Trevi Therapeutics, Inc. (NASDAQ:TRVI) looks well-established to capitalize on this clinical momentum.

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, develops Haduvio, an oral extended-release therapy for chronic cough across IPF, Non-IPF ILD, and refractory chronic cough.

While we acknowledge the potential of TRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Cheap Gold Stocks to Buy Now and 15 Best AI Stocks to Watch in December 2025.

Disclosure: None.